On 10 December 2025, Polpharma Biologics announced that it has entered a licence agreement with Brazilian pharmaceutical company, Libbs Farmacêutica, for the commercialisation of an unnamed biosimilar for autoimmune diseases in Brazil.
Under the agreement, Polpharma retains responsibility for the development and manufacturing of the biosimilar, while Libbs has exclusive rights for the commercialisation, marketing and distribution of the product in Brazil.
The deal between Polpharma and Libbs follows a licensing agreement between Polpharma and MS Pharma in September 2025 for the commercialisation in the MENA region of biosimilars to guselkumab (PB019, referencing Janssen’s Tremfya®), ocrelizumab (PB018, referencing Roche’s Ocrevus®) and vedolizumab (PB016, referencing Takeda’s Entyvio®). In August 2025, Polpharma Biologics entered into a global licensing agreement (excluding the MENA region) with Fresenius Kabi for the commercialisation of PB016 (vedolizumab).